Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
|Articles|November 1, 2006
Breast cancer risk in subset of OC users
Oral contraceptives (OCs) are associated with a small increase in premenopausal breast cancer risk, especially in parous women who use them for 4 or more years before a first full-term pregnancy, according to a new meta-analysis.
Advertisement
Advertisement
Related to this article
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Neurokinin receptor antagonists improve menopausal sleep disturbance
2
TMS 2026: HSDD biopsychosocial approach, night sweats red flags, misread WHI data
3
Brain fog at menopause: Separating normal change from dementia
4
Red flags that point beyond menopause in patients with night sweats
5